論文引用

1. Quimby JM, Webb TL, Gibbons DS, et al. Evaluation of intrarenal mesenchymal stem cell injection for treatment of chronic kidney disease in cats: a pilot study. J Feline Med Surg. 13(6):418-426, 2011.
2. Quimby JM, Webb TL, Habenicht LM, et al. Safety and efficacy of intravenous infusion of allogeneic cryopreserved mesenchymal stem cells for treatment of chronic kidney disease in cats: results of three sequential pilot studies. Stem Cell Res Ther. 4(2):48, 2013
4. Liang J, Zhang H, Hua B, et al. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis. 69(8):1423-1429, 2010.
5. Effects of Adipose Derived Stem Cell Therapy in Women With Premature Ovarian Failure
6. Sun L, Wang D, Liang J, et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum. 62(8):2467-2475, 2010. 10. El-AnsaryM, Saadi G, Abd El-Hamid S. Mesenchymal stem cells are a rescue approach for recovery of deteriorating kidney function. Nephrology (Carlton). 17(7):650-657, 2012.
7.Effectiveness and Safety of Intracavernosal Administration of Autologous Adipose-Derived Regenerative Cells for Treatment of Erectile Dysfunction
8.”It is a Real” The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure 15. Fang B, Mai L, Li N, et al. Favorable response of chronic refractory immune thrombocytopenic purpura to mesenchymal stem cells. Stem Cells Dev. 21(3):497-502, 2012.
9.The Use of Autologous Adipose Tissue-Derived Mesenchymal Stem Cell (AdMSC) for the Improvement of Erectile and Cardiac Function in Aging Men
16. Xiao Y, Jiang ZJ, Pang Y, et al. E fficacy and sa fety o f mesenchymal stromal cell treatment from related donors for patients with refractory aplastic anemia. Cytotherapy. 15(7):760- 766, 2013. 19. http://www.tigenix.com/public/uploads/files/Cx611%20in%20RA. pdf
21. Wang D, Zhang H, Cao M, et al. Efficacy o f allogeneic mesenchymal stem cell transplantation in patients with drugresistant polymyositis and dermatomyositis. Ann Rheum Dis. 70(7):1285-1288, 2011.
23. http://www.osiris.com/pdf/Crohn’s_Ph_II_Handout.pdf
24. Duijvestein M, Vos AC, Roelofs H, et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn’s disease: results of a phase I study. Gut. 59(12):1662-1669, 2010.
25. Lazebnik LB, Konopliannikov AG, Kniazev OV, et al. Use of allogeneic mesenchymal stem cells in the treatment of intestinal inflammatory diseases. Ter Arkh. 82(2):38-43, 2010.
26. Lazebnik LB, Kniazev OV, Konopliannikov AG, et al. Allogeneic mesenchymal stromal cells in patients with ulcerative colitis: two years of observation. Eksp Klin Gastroenterol. (11):3-15, 2010.
27. Lazebnik LB, Knyazev OV, Parfenov AI, et al. Optimization of cell therapy in patients with inflammatory bowel diseases. Ter Arkh. 84(8):10-17, 2012.
29. Pérez-Simón JA, Tabera S, Sarasquete ME, et al. Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura. Cytotherapy. 11(6):698-705, 2009.
37. Hu J, Yu X, Wang Z, et al. Long term effects of the implantation of Wharton’s jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus. Endocr J. 60(3):347-357, 2013.
38. Jiang R, Han Z, Zhuo G, et al. Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study. Front Med. 5(1):94-100, 2011.
44. Catchpole B, Ristic JM, Fleeman LM, et al. Canine diabetes mellitus: can old dogs teach us new tricks? Diabetologia. 48(10):1948-1956, 2005.
46. Kharaziha P, Hellström PM, Noorinayer B, et al. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur J Gastroenterol Hepatol. 21(10):1199-1205, 2009.
49. El-Ansary M, Abdel-Aziz I, Mogawer S, et al. Phase II trial: undifferentiated versus differentiated autologous mesenchymal stem cells transplantation in Egyptian patients with HCV induced liver cirrhosis. Stem Cell Rev. 8(3):972-981, 2012.
50. Zhang Z, Lin H, Shi M, et al. Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients. J Gastroenterol Hepatol. 27 Suppl 2:112- 120, 2012.
51. Shi M, Zhang Z, Xu R, et al. Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients. Stem Cells Transl Med. 1(10):725-731, 2012.
52. Lin H, Zhang Z, Shi M, et al. Prospective controlled trial of safety of human umbilical cord derived-mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Zhonghua Gan Zang Bing Za Zhi. 20(7):487-491, 2012.
53.Phase 1//2 Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis
54.Open, Prospective Trial of Treatment of Autism Spectrum Disorders (ASD) Using Intravenous Infusion of Umbilical Cord Tissue Mesenchymal Stem Cells (UC-MSC)
61.Umbilical Cord Mesenchymal Stem Cell Infusion With Liraglutide in Type 2 Diabetes Mellitus
62.Phase Ι/Π Study of Stem Cell Therapy in Patients With Autism
63.A Randomized, Blinded, Placebo-controlled, Crossover Study to Assess the Efficacy of Stem Cells From Autologous Umbilical Cord Blood to Improve Language and Behavior in Children With Autism
73. http://www.osiris.com/prod_cardiac.php
74. Bang OY, Lee JS, Lee PH, et al. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol. 57(6):874-882, 2005.
75. Lee JS, Hong JM, Moon GJ, et al. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells. 28(6):1099-1106, 2010.
76. Honmou O, Houkin K, Matsunaga T, et al. Int ravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain. 134(Pt 6):1790-1807, 2011.
77. Bhasin A, Srivastava MV, Kumaran SS, et al. Autologous mesenchymal stem cells in chronic stroke. Cerebrovasc Dis Extra. 1(1):93-104, 2011.
84. Odinak MM, Bisaga GN, Novitskiĭ AV, et al. Transplantation of mesenchymal stem cells in multiple sclerosis. Zh Nevrol Psikhiatr Im S S Korsakova. 111(2 Pt 2):72-76, 2011.
85.Effect and Side Effect of Mesenchymal Stem Cell in Multiple Sclerosis
97.M. Albersen, T. M. Fandel, G. Lin et al., “Injections of adipose tissue-derived stem cells and stem cell lysate improve recovery of erectile function in a rat model of cavernous nerve injury,” The Journal of Sexual Medicine, vol. 7, no. 10, pp. 3331–3340, 2010. View at Publisher · View at Google Scholar · View at Scopus 99. Jin JL, Liu Z, Lu ZJ, et al. Safety and efficacy of umbilical cord mesenchymal stem cell therapy in hereditary spinocerebellar ataxia. Curr Neurovasc Res. 10(1):11-20, 2013.
100. Lee PH, Kim JW, Bang OY, et al. Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy. Clin Pharmacol Ther. 83(5):723-730, 2008.
101. Lee PH, Lee JE, Kim HS, et al. A randomized t rial o f mesenchymal stem cells in multiple system atrophy. Ann Neurol. 72(1):32-40, 2012.
104. Li M, Yu A, Zhang F, et al. Treatment of one case of cerebral palsy combined with posterior visual pathway injury using autologous bone marrow mesenchymal stem cells. J Transl Med. 10:100, 2012.